SCHEMBL2384785

SCHEMBL2384785

COC(=O)C(C)NC(=O)c1c(O)c2c(F)cccc2n(C)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
NLRP3 Q96P20 1/20 0.46
HDAC4 P56524 1/20 0.42
HIF1A Q16665 4/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
POLB P06746 1/20 0.40
PABPC1 P11940 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HTT P42858 1/20 0.40
CNR2 P34972 2/20 0.39
CNR1 P21554 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
BRPF1 P55201 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384782 1.00 L3MBTL1 (0.47) L3MBTL1MEN1KMT2ACRHBPCRHR2
SCHEMBL2382505 0.89 L3MBTL1 (0.51) L3MBTL1MEN1KMT2ACRHBPCRHR2
SCHEMBL12254450 0.89 L3MBTL1 (0.48) L3MBTL1MEN1KMT2ACRHBPCRHR2
SCHEMBL2382509 0.89 L3MBTL1 (0.51) L3MBTL1MEN1KMT2ACRHBPCRHR2
SCHEMBL2384484 0.88 L3MBTL1 (0.47) L3MBTL1MEN1KMT2ANLRP3HDAC4
SCHEMBL2384480 0.88 L3MBTL1 (0.47) L3MBTL1MEN1KMT2ANLRP3HDAC4
SCHEMBL2385866 0.87 L3MBTL1 (0.47) L3MBTL1MEN1KMT2AHDAC4HIF1A
SCHEMBL2385869 0.87 L3MBTL1 (0.47) L3MBTL1MEN1KMT2AHDAC4HIF1A
SCHEMBL2383515 0.87 HDAC4 (0.53) L3MBTL1MEN1KMT2ANLRP3HDAC4
SCHEMBL2383516 0.87 HDAC4 (0.53) L3MBTL1MEN1KMT2ANLRP3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4035/4885MEN1 3474/4885KMT2A 942/4885
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4024/4885MEN1 3364/4885KMT2A 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.